Literature DB >> 6949629

A method for obtaining high quality chromosome preparations from single hemopoietic colonies on a routine basis.

I D Dubé, C J Eaves, D K Kalousek, A C Eaves.   

Abstract

The need for improved methodology to facilitate cytogenetic analysis of hemopoietic stem cell populations, particularly in studies of the hemopoietic malignancies, has been recognized for a number of years. Since primitive hemopoietic cells can be stimulated to form colonies of identifiable progeny under appropriate conditions in vitro, it should in theory, be possible to obtain such information. However, hemopoietic colonies of human origin rarely contain more than 1000 cells, and in handling such small samples, cell loss has historically been a major problem. We now describe a method that has allowed from two up to more than 50 metaphases per colony to be obtained from most erythroid and granulopoietic colonies harvested individually from standard methylcellulose assay cultures. Of key importance is the selection of large but still immature colonies and the use of polylysine coated slides, which ensures recovery of 80 - 90% of the sample. The method yields reproducibly high quality metaphases suitable for analysis after G, Q, and fluorescent-reverse banding. Cytogenetic analysis of 58 colonies removed individually from cultures initiated with a mixture of male and female cells showed both male and female colonies to be present as expected. In all instances only one type of metaphase was ever found in a single colony. A procedure for measuring the incidence of sister chromatid exchange (SCE) in the progeny of primitive hemopoietic progenitors has also been established. SCE values obtained for 1-2-week-old colonies derived from normal progenitors were similar to previously published normal SCE values. Preliminary analysis of erythroid and granulocytic colonies from one patient with polycythemia vera (PV) and two patients with chronic myelogenous leukemia (CML) indicate that preparations of equal quality are obtained from such individuals and thus, for the first time, the Ph1 chromosome could be readily demonstrated in erythroid colonies. Further application of this method to the investigation of patients with myeloproliferative disease is now underway.

Entities:  

Mesh:

Year:  1981        PMID: 6949629     DOI: 10.1016/0165-4608(81)90080-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Acute nonlymphocytic leukemia (M2) with chromosome abnormality trisomy 4 developing eight years after radiation therapy for breast cancer.

Authors:  S Yokota; M Taniwaki; T Okuda; T Maekawa; K Nishida; S Misawa; T Takino; T Abe; Y Urata
Journal:  Blut       Date:  1989-01

2.  T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia.

Authors:  A A Fauser; L Kanz; K J Bross; G W Löhr
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

3.  Growth of normal versus leukemic bone marrow cells in long term culture from acute lymphoblastic and myeloblastic leukemias.

Authors:  R Schiró; L H Coutinho; A Will; J Chang; N G Testa; T M Dexter
Journal:  Blut       Date:  1990-11

4.  Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha.

Authors:  G Egert; L Kanz; G W Löhr; A A Fauser
Journal:  Blut       Date:  1990-05

5.  Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases.

Authors:  L Coulombel; C Eaves; D Kalousek; C Gupta; A Eaves
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

6.  Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells.

Authors:  A C Eaves; J D Cashman; L A Gaboury; D K Kalousek; C J Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  Cytogenetic analysis of leukaemic colonies from acute and chronic myelogenous leukaemia.

Authors:  J M Trent; J R Davis; B G Durie
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

8.  Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy.

Authors:  E M Weissinger; K Oettrich; C Evans; H-G Genieser; F Schwede; M Dangers; E Dammann; H-J Kolb; H Mischak; A Ganser; W Kolch
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.